Advanced Rheumatology Course (ARC): All Activities

ARC is a series of 19 activities that provides foundational knowledge and sets up new rheumatology professionals for clinical practice success.

$239900

Product Code: ADV-ALL-EXP25

Pricing Info: Member: $1999
Non-Member: $2399

Activity Format: Self-Paced

Topic(s): Basic & Clinical Sciences, Infections & Related Arthritides, Lupus, Rheumatoid Arthritis

Start Date: Wednesday, August 16, 2023, 12:00 AM

End Date: Saturday, August 15, 2026, 11:55 PM

Credit: CME, Participation

Target Audience: Advanced Practice Nurses, Counselors, Nurses, Occupational Therapists, Pharmacists, Practice Administrators, Primary Care Providers, Physical Therapists, Physician Assistants, Researchers, Residents

Curriculum: Advanced Rheumatology Course

CME: 25.00

Description

The Advanced Rheumatology Course is a 19-activity series for advanced practice providers and other professionals who need a deeper dive into rheumatology. The series covers how to assess and manage patients with rheumatic disease, develop strategies to integrate NP/PAs into rheumatology practice, and improve access to care for patients. The advanced information will help experienced practice providers function well in rheumatology and foster inter-professional collaboration.

Advanced Rheumatology Course Series

This activity includes all activities in the series.

Registration is discounted for ACR/ARP members. If you are not a member, consider joining ACR/ARP.

Target Audience

Advanced practice nurses and physician assistants. Fellows-in training, residents, students, primary care providers, physical therapists, and researchers may also benefit.

Learning Objectives

Upon completion of this activity, participants should be able to:

Assess and manage patients with rheumatic diseases as part of an interprofessional collaborative care team
Develop strategies to integrate the nurse practitioner and physician assistant into a collaborative rheumatology practice
Assist in decreasing wait times for appointments and improve access to care for patients with rheumatic disease by improving the competence and performance of nurse practitioners and physician assistants in a collaborative rheumatology practice

CE & MOC Information

CME

ACCME Accreditation Statement

The American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA Designation Statement

The American College of Rheumatology designates this enduring material for a maximum of 25.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

See the ACR's CME Mission Statement. For more information, download the AMA PRA Booklet.

CME credit must be claimed by August 14, 2026, at 11:59 PM ET.

Financial Relationships Disclosures

ACR Disclosure Statement

It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners' and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at http://accme.org .

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity.

Nature of Financial Relationships

All individuals involved or able to influence the content of this accredited activity have disclosed to the editorial team and audience any/all financial or other relationship(s) including, but not limited to:

Advisor or review panel member
Consultant
Employee
Officer or Board Member
Grant/research support
Speaker/honoraria includes speaker’s bureau, symposia, and expert witness
Independent contractor
Executive role and/or ownership interest
Royalties and/or patent beneficiary
Intellectual property/patents
Stock options or bond holdings in a for-profit corporation or self-directed pension plan
Private investigator
Expert witness
Equity interest
Other: specify details

None: Has no relevant financial relationship(s) with ineligible companies to disclose.

All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated.

Faculty

ARC01: Musculoskeletal Structure And Function And Inflammation And Immunity

Authors/Planners

Kenneth S. O’Rourke, MD - No relevant financial relationships to disclose
Rachel M. Wolfe, MD - No relevant financial relationships to disclose

Editors and Reviewers

Daniel Schaffer, MD – No relevant financial relationships to disclose
Anneke Smith – No relevant financial relationships to disclose
Ben Smith, DMSc, PA-C, DFAAPA – No relevant financial relationships to disclose

ARC02: Framework for Clinical Decision Making in Rheumatology

Author

Megan Lockwood, MD - No relevant financial relationships to disclose

Editors and Reviewers

Jennifer Grossman, MD - No relevant financial relationships to disclose
Anneke Smith – No relevant financial relationships to disclose
Sonam Kiwalkar, MD – No relevant financial relationships to disclose

ARC03: Laboratory Evaluation of Rheumatic Disease

Author

Beth Jonas, MD – No relevant financial relationships to disclose

Editors and Reviewers

Laurie Hughell, MPH, PA-C - No relevant financial relationships to disclose
Anneke Smith – No relevant financial relationships to disclose
Ben Smith, DMSc, PA-C, DFAAPA – No relevant financial relationships to disclose

ARC04: Imaging of Arthritis

Author

Beth Jonas, MD – No relevant financial relationships to disclose

Editors and Reviewers

Laurie Hughell, MPH, PA-C - No relevant financial relationships to disclose
Anneke Smith – No relevant financial relationships to disclose
Ben Smith, DMSc, PA-C, DFAAPA – No relevant financial relationships to disclose

ARC05: Coding And Practice Issues

Author

J. Eugene Huffstutter, MD - No relevant financial relationships to disclose

Editors and Reviewers

Fredrica Smith, MD - No relevant financial relationships to disclose
Julie Lahti - No relevant financial relationships to disclose
Ben Smith, DMSc, PA-C, DFAAPA - No relevant financial relationships to disclose

ARC06: Therapeutic Interventions And Resources

Authors/Planners

Donna Everix, MPH, PT - No relevant financial relationships to disclose
Jennifer Trizuto, DPT - No relevant financial relationships to disclose

Editors and Reviewers

Marie Westby, PT, PhD - Janssen Canada⁵; Ended 2020; Pfizer⁵; Ended 2020
Julie Lahti - No relevant financial relationships to disclose
Ben Smith, DMSc, PA-C, DFAAPA - No relevant financial relationships to disclose

ARC07: Osteoarthritis

Authors/Planners

Abhijeet Danve, MD – AbbVie/Abbott¹; Novartis¹
Yuliya Afinogenova, MD - No relevant financial relationships to disclose
Swetha Alexander, MD - No relevant financial relationships to disclose

Editors and Reviewers

Janeth Yinh, MD – No relevant financial relationships to disclose
Anneke Smith – No relevant financial relationships to disclose
Sonam Kiwalkar, MD – No relevant financial relationships to disclose

ARC08: RA and Seronegative Inflammatory Arthropathies

Author

Gregory C. Gardner, MD, MACP – No relevant financial relationships to disclose

Editors and Reviewers

Sheila Arvikar, MD – No relevant financial relationships to disclose
Julie Lahti - No relevant financial relationships to disclose
Sonam Kiwalkar, MD – No relevant financial relationships to disclose

ARC09: Systemic Lupus Erythematosus

Authors/Planners

Mary Chester Wasko, MD, AbbVie/Abbott²; AstraZeneca²; EMD Serono²; GlaxoSmithKlein²; HGS²; Roche²
Joanna Marco, MD – No relevant financial relationships to disclose

Editors and Reviewers

Paul Monach, MD, PhD – Celgene¹; Chemocentryx⁶; Kiniksa¹⁶
Anneke Smith – No relevant financial relationships to disclose
Marcy Bolster, MD – AbbVie²; American Board of Internal Medicine: Chair, ABIM Rheumatology Board⁶; Amgen²; Corbus Pharmaceuticals²; Cumberland²; Genentech²; Gilead Sciences⁵; Johnson & Johnson¹; Pfizer²

ARC10: Systemic Inflammatory Conditions

Authors/Planners

Jason Kolfenbach, MD: ChemoCentryx⁵
Tara Skorupa, MD: No relevant financial relationships to disclose

Editors and Reviewers

Zsuzsanna McMahon – No relevant financial relationships to disclose
Marcy Bolster, MD – AbbVie²; American Board of Internal Medicine: Chair, ABIM Rheumatology Board⁶; Amgen²; Corbus Pharmaceuticals²; Cumberland²; Genentech²; Gilead Sciences⁵; Johnson & Johnson¹; Pfizer²
Julie Lahti – No relevant financial relationships to disclose

ARC11: Vasculitis, Arteritis and PMR

Authors/Planners

Anisha Dua, MD - AbbVie/Abbott^{5, 8}; ChemoCentryx⁵; Novartis⁵
Josh Waytz, MD – No relevant financial relationships to disclose

Editors and Reviewers

Paul Monach, MD, PhD – Celgene¹; Chemocentryx⁶; Kiniksa
Anneke Smith – No relevant financial relationships to disclose
Marcy Bolster, MD – AbbVie²; American Board of Internal Medicine: Chair, ABIM Rheumatology Board⁶; Amgen²; Corbus Pharmaceuticals²; Cumberland²; Genentech²; Gilead Sciences⁵; Johnson & Johnson¹; Pfizer²

ARC12: Crystal-Induced Arthropathies

Author

Puja Khanna, MD – DYVE²; Horizon^1,2,5; Select^1,2

Editors and Reviewers

Chio Yokose, MD – No relevant financial relationships to disclose
Anneke Smith – No relevant financial relationships to disclose
Sonam Kiwalkar, MD – No relevant financial relationships to disclose

ARC13: Pain Syndromes

Author

Andrew Heisler, MD – No relevant financial relationships to disclose

Editors and Reviewers

Sonam Kiwalkar, MD – No relevant financial relationships to disclose
Christine Stamatos, DNP – No relevant financial relationships to disclose
Julie Lahti – No relevant financial relationships to disclose

ARC14: Spondyloarthritis

Authors/Planners

Atul Deodhar, MD - AbbVie/Abbott⁵²⁸; Amgen⁵²⁸; BMS⁵²⁸; Boheringer Ingelheim⁵²⁸; Celgene⁵²⁸; Gilead⁵²⁸; Glapagos⁵²⁸; Janssen⁵²⁸; Lilly⁵²⁸; Novartis⁵²⁸; Pfizer⁵²⁸; UCB⁵²⁸
Anand Kumthekar, MD – No relevant financial relationships to disclose

Editors and Reviewers

Abhijeet Danve, MD – AbbVie/Abbott¹; Novartis¹
Anneke Smith – No relevant financial relationships to disclose
Sonam Kiwalkar, MD – No relevant financial relationships to disclose

ARC15: Infection-Related Arthritis

Authors/Planners

Robert A. Kalish, MD – No relevant financial relationships to disclose
Janet Hong, MD – No relevant financial relationships to disclose
Frank Scangarello, MD, PhD – No relevant financial relationships to disclose

Editors and Reviewers

Michael Battistone, MD – American Board of Internal Medicine Rheumatology Exam Committee⁶: Advisor or Review Panel member
Anneke Smith – No relevant financial relationships to disclose
Marcy Bolster, MD – AbbVie²; American Board of Internal Medicine: Chair, ABIM Rheumatology Board⁶; Amgen²; Corbus Pharmaceuticals²; Cumberland²; Genentech²; Gilead Sciences⁵; Johnson & Johnson¹; Pfizer²

ARC16: Osteoporosis And Other Metabolic Bone Disorders

Author

Sarah Keller, MD – No relevant financial relationships to disclose

Editors and Reviewers

Alfred Denio, MD – Abbvie⁸; Bristol-Myers Squibb⁵
Marcy Bolster, MD – AbbVie²; American Board of Internal Medicine: Chair, ABIM Rheumatology Board⁶; Amgen²; Corbus Pharmaceuticals²; Cumberland²; Genentech²; Gilead Sciences⁵; Johnson & Johnson¹; Pfizer²
Julie Lahti – No relevant financial relationships to disclose

ARC17: Comprehensive Overview of Juvenile Idiopathic Arthritis (JIA)

Author

Betsy Roth-Wojcicki, RN, MS, CPNP-PC - No relevant financial relationships to disclose

Editors and Reviewers

Heather Benham, APRN, CPNP, DNP, RhMSUS – No relevant financial relationships to disclose
Anneke Smith - No relevant financial relationships to disclose
Ben Smith, DMSc, PA-C, DFAAPA – No relevant financial relationships to disclose

ARC18: Comprehensive Overview of Pediatric Connective Tissue Diseases (CTD)

Author

Heather Benham, DNP, APRN, CPNP-PC, RhMSUS – No relevant financial relationships to disclose

Editors and Reviewers

Natasha Ruth, MD, MS – No relevant financial relationships to disclose
Marcy Bolster, MD – AbbVie²; American Board of Internal Medicine: Chair, ABIM Rheumatology Board⁶; Amgen²; Corbus Pharmaceuticals²; Cumberland²; Genentech²; Gilead Sciences⁵; Johnson & Johnson¹; Pfizer²
Julie Lahti – No relevant financial relationships to disclose

ARC19: Pediatric Noninflammatory Musculoskeletal Pain

Author

Bethany A. Marston, MD – No relevant financial relationships to disclose

Editors and Reviewers

Susan Shenoi, MS, MBBS, RhMSUS – Pfizer⁵
Julie Lahti - No relevant financial relationships to disclose
Sonam Kiwalkar, MD – No relevant financial relationships to disclose

*All of the relevant financial relationships listed for these individuals have been mitigated.

Acknowledgement of Commercial Support

The project was supported by Grant number 1 NU58DP006908-03-00 – Component A; Developing and Disseminating Programs to Build Sustainable Lupus Awareness, Knowledge, Skills and Partnerships. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Department of Health and Human Services, Centers for Disease Control and Prevention.

Educational Activity Policies

See ACR educational activity policies, including the online enduring activity refund policy.

Activities

ARC01: Musculoskeletal Structure and Function and Inflammation and Immunity

ACTIVITY OVERVIEW The Advanced Rheumatology Course is a 19-activityseries for advanced practice providers and other professionals who need adeeper dive into rheumatology. The series covers how to assess and manage patients with rheumatic disease, develop strategies to integrate NP/PAs into rheumatology practice, and improve access to care for patients. The advanced information will help experienced practice providers function well in rheumatology and foster inter-professional collaboration. In this activity, review the basic framework of the musculoskeletal system and explore the key principles of immune system operation and autoimmunity. ADVANCED RHEUMATOLOGY COURSE SERIES This activity is part of a series. See the other activities in the series below. * Advanced Rheumatology Course: All Activities * Activity 1: MusculoskeletalStructure And Function And Inflammation And Immunity * Activity 2: Framework forClinical Decision Making in Rheumatology * Activity 3: LaboratoryEvaluation of Rheumatic Disease * Activity 4: Imaging ofArthritis * Activity 5: Coding AndPractice Issues * Activity 6: TherapeuticInterventions And Resources * Activity 7: Osteoarthritis * Activity 8: RA andSeronegative Inflammatory Arthropathies * Activity 9: Systemic LupusErythematosus * Activity 10: SystemicInflammatory Conditions: Inflammatory Myopathy * Activity 11: Vasculitis,Arteritis and PMR * Activity 12: Crystal-InducedArthropathies * Activity 13: Pain Syndromes * Activity 14:Spondylarthritis * Activity 15:Infection-Related Arthritis * Activity 16: OsteoporosisAnd Other Metabolic Bone Disorders * Activity 17: ComprehensiveOverview of Juvenile Idiopathic Arthritis (JIA) * Activity 18: ComprehensiveOverview of Pediatric Connective Tissue Diseases (CTD) * Activity 19: PediatricNoninflammatory Musculoskeletal Pain Registration is discounted for ACR/ARP members. If you are not a member, consider joining ACR/ARP. TARGET AUDIENCE Advanced practice nurses, physician assistants, Rheumatology fellows-intraining, residents, students, primary care providers and researchers may also benefit. LEARNING OBJECTIVES Uponcompletion of this activity, participants should be able to: * Describethe structure and function of bone, skeletal muscle, articular cartilage, andconnective tissue * Classifythe different types of synovial joints and periarticular tissues * Articulatethe structure and clinical relevance of functional and dysfunctionalendothelium * Identifythe principal cells and functions of the innate and adaptive immune systems * Describethe physiologic processes in inflammation, immunity, and immune dysregulation * Discussthe impact of evolving knowledge of molecular biology on the diagnosis andtreatment of rheumatic diseases CE &MOC INFORMATION ACCME ACCREDITATION STATEMENT The American Collegeof Rheumatology is accredited by the Accreditation Council for ContinuingMedical Education (ACCME) to provide continuing medical education forphysicians. AMA DESIGNATIONSTATEMENT The American College of Rheumatology designates this enduring materialfor a maximum of 1.50 _AMA PRA Category 1 Credit(s)_™. Physicians should claimonly the credit commensurate with the extent of their participation in theactivity. See the ACRs CME Mission Statement. For more information,download the AMA PRA Booklet. _CME credit must be claimed by August 14, 2026, at 11:59 PMET._ FINANCIAL RELATIONSHIP DISCLOSURES ACR DISCLOSURE STATEMENT It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org. Inaccordance with the ACCME Standards for Integrity and Independence inAccredited Continuing Education, ACR has implemented mechanisms prior to theplanning and implementation of this CME activity to identify and mitigate allrelevant financial relationships for all individuals in a position to controlthe content of this CME activity. NATUREOF FINANCIAL RELATIONSHIPS All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to: * Advisor or review panelmember * Consultant * Employee * Officer or Board Member * Grant/research support * Speaker/honoraria includes speaker’s bureau,symposia, and expert witness * Independent contractor * Executive role and/or ownership interest * Royalties and/or patent beneficiary * Intellectual property/patents * Stock options or bond holdings in a for-profitcorporation or self-directed pension plan * Private investigator * Expert witness * Equity interest * Other: _specify details_ None: Has no relevant financialrelationship(s) with ineligible companies to disclose. All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated. AUTHORS/PLANNERS * Kenneth S. O’Rourke, MD - No relevant financial relationships to disclose * Rachel M. Wolfe, MD - No relevant financial relationships to disclose CONTENT REVIEWERS * Daniel Schaffer, MD – No relevant financial relationships to disclose * Anneke Smith – No relevant financial relationships to disclose * Ben Smith, DMSc, PA-C, DFAAPA – No relevant financial relationships to disclose ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT The project was supported by Grant number 1 NU58DP006908-03-00 – Component A; Developing and Disseminating Programs to Build Sustainable Lupus Awareness, Knowledge, Skills and Partnerships. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Department of Health and Human Services, Centers for Disease Control and Prevention. EDUCATIONAL ACTIVITY POLICIES See ACR educational activity policies, including the online enduring activity refund policy.

ARC02: Framework for Clinical Decision Making in Rheumatology

ACTIVITY OVERVIEW The Advanced Rheumatology Course is a19-activity series for advanced practice providers and other professionals whoneed a deeper dive into rheumatology. The series covers how to assess and manage patients with rheumaticdisease, develop strategies to integrate NP/PAs into rheumatology practice, andimprove access to care for patients. The advanced information will helpexperienced practice providers function well in rheumatology and fosterinter-professional collaboration. In this activity, learn to generate comprehensive frameworks for clinical decision-making, which will enable you to effectively navigate your daily tasks in the rheumatology clinic. ADVANCED RHEUMATOLOGYCOURSE SERIES This activity is part of a series. See the otheractivities in the series below. * Advanced Rheumatology Course: All Activities * ARC01: MusculoskeletalStructure And Function And Inflammation And Immunity * ARC02: Framework forClinical Decision Making in Rheumatology * ARC03: Laboratory Evaluationof Rheumatic Disease * ARC04: Imaging of Arthritis * ARC05: Coding and PracticeIssues * ARC06: TherapeuticInterventions And Resources * ARC07: Osteoarthritis * ARC08: RA and SeronegativeInflammatory Arthropathies * ARC09: Systemic LupusErythematosus * ARC010: SystemicInflammatory Conditions: Inflammatory Myopathy * ARC11: Vasculitis, Arteritisand PMR * ARC12: Crystal-InducedArthropathies * ARC13: Pain Syndromes * ARC14: Spondyloarthritis * ARC15: Infection-RelatedArthritis * ARC16: Osteoporosis AndOther Metabolic Bone Disorders * ARC17: ComprehensiveOverview of Juvenile Idiopathic Arthritis (JIA) * ARC18:Comprehensive Overviewof Pediatric Connective Tissue Diseases (CTD) * ARC19: Pediatric Noninflammatory MusculoskeletalPain Registrationis discounted for ACR/ARP members. If you are not a member, considerjoining ACR/ARP. TARGET AUDIENCE Advanced practice nurses and physician assistants. Fellows-in training, residents, students, primary care providers, physical therapists, and researchers may also benefit. LEARNING OBJECTIVES Upon completion of this activity, participants should be able to: * Screen patients with pain in order to classify them into three classes, which include inflammatory arthropathies, degenerative and mechanical arthropathies, and nonarticular and central pain processing disorders * Perform a complete medical history, including assessment of a chief complaint, history of present illness, past medical history, family history, social history, use of therapeutics, and review of systems * Conduct a general physical exam for patients with suspected rheumatic disorders * Examine patients with suspected rheumatic disorders including the basic components of a musculoskeletal examination such as inspection/appearance, palpation, range of motion, and functional assessment * Outline a differential diagnosis to create a framework for clinical decision making for patients with rheumatic disorders * Spot worrisome ‘red flags’ for patients with rheumatic disorders CE & MOC INFORMATION ACCME ACCREDITATION STATEMENT The American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AMA DESIGNATION STATEMENT The American College of Rheumatology designates this enduring material for a maximum of 1.00 _AMA PRA Category 1 Credit™_. Physicians should claim only the credit commensurate with the extent of their participation in the activity. See the ACRs CME Mission Statement. For more information, download the AMA PRA Booklet. _CME credit must be claimed by August 14, 2026, at 11:59 PM ET._ FINANCIAL RELATIONSHIP DISCLOSURES ACR DISCLOSURE STATEMENT It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org. In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity. NATUREOF FINANCIAL RELATIONSHIPS Allindividuals that participate in an ACR-sponsored activity and are able tochange content or influence the content of the activity must disclose to theplanning committee and audience all financial or other relationships withineligible companies including, but not limited to: * Advisor or review panel member * Consultant * Employee * Officer or Board Member * Grant/research support * Speaker/honoraria includes speaker’s bureau, symposia, and expertwitness * Independent contractor * Executive role and/or ownership interest * Royalties and/or patent beneficiary * Intellectual property/patents * Stock options or bond holdings in a for-profit corporation orself-directed pension plan * Private investigator * Expert witness * Equity interest * Other: _specify details_ None: Has no relevant financialrelationship(s) with ineligible companies to disclose. All participants that createdand/or were able to influence the content and delivery of this activity reportedthe following disclosures. All of the relevant financial relationships listedhave been mitigated. AUTHOR * Megan Lockwood, MD - No relevant financial relationships to disclose EDITORS AND REVIEWERS * Jennifer Grossman, MD - No relevant financial relationships to disclose * Anneke Smith – No relevant financial relationships to disclose * Sonam Kiwalkar, MD – No relevant financial relationships to disclose ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT The project was supported by Grant number 1 NU58DP006908-03-00 – Component A; Developing and Disseminating Programs to Build Sustainable Lupus Awareness, Knowledge, Skills and Partnerships. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Department of Health and Human Services, Centers for Disease Control and Prevention. EDUCATIONAL ACTIVITY POLICIES See ACR educational activity policies, including the online enduring activity refund policy.

ARC03: Laboratory Evaluation of Rheumatic Disease

ACTIVITY OVERVIEW The Advanced Rheumatology Course is a19-activity series for advanced practice providers and other professionals whoneed a deeper dive into rheumatology. The series covers how to assess and manage patients with rheumaticdisease, develop strategies to integrate NP/PAs into rheumatology practice, andimprove access to care for patients. The advanced information will helpexperienced practice providers function well in rheumatology and fosterinter-professional collaboration. In this activity, learn laboratory tests for the evaluation, diagnosis, and treatment of the most prevalent rheumatologic conditions. ADVANCED RHEUMATOLOGY COURSE SERIES This activity is part of a series. See the other activities in the series below. * Advanced Rheumatology Course: All Activities * ARC01: Musculoskeletal Structure And Function And Inflammation And Immunity * ARC02: Framework for Clinical Decision Making in Rheumatology * ARC03: Laboratory Evaluation of Rheumatic Disease * ARC04: Imaging of Arthritis * ARC05: Coding and Practice Issues * ARC06: Therapeutic Interventions And Resources * ARC07: Osteoarthritis * ARC08: RA and Seronegative Inflammatory Arthropathies * ARC09: Systemic Lupus Erythematosus * ARC010: Systemic Inflammatory Conditions: Inflammatory Myopathy * ARC11: Vasculitis, Arteritis and PMR * ARC12: Crystal-Induced Arthropathies * ARC13: Pain Syndromes * ARC14: Spondyloarthritis * ARC15: Infection-Related Arthritis * ARC16: Osteoporosis And Other Metabolic Bone Disorders * ARC17: Comprehensive Overview of Juvenile Idiopathic Arthritis (JIA) * ARC18:Comprehensive Overview of Pediatric Connective Tissue Diseases (CTD) * ARC19: Pediatric Noninflammatory Musculoskeletal Pain Registration is discounted for ACR/ARP members. If you are not a member, consider joining ACR/ARP. TARGET AUDIENCE Advanced practice nurses and physician assistants. Fellows-in training, residents, students, primary care providers, physical therapists, and researchers may also benefit. LEARNING OBJECTIVES Upon completion of this activity, participants should be able to: * Order appropriate laboratory testsfor the evaluation, diagnosis, and prognosis of the most common rheumaticdiseases * Recognize the serologicassociations of rheumatic diseases * Apply the concepts of sensitivity,specificity, likelihood ratio, and the receiver operator characteristics (ROC)curve of a diagnostic test to the clinical practice of laboratory testing * Identify lab tests that areroutinely used in monitoring activity of rheumatic diseases * List laboratory tests that arepart of monitoring for toxicity of antirheumatic therapies CE & MOC INFORMATION ACCME ACCREDITATION STATEMENT The American College of Rheumatology (ACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AMA DESIGNATION STATEMENT The American College of Rheumatology designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. See the ACRs CME Mission Statement. For more information, download the AMA PRA Booklet. _CME credit must be claimed by August 14, 2026, at 11:59 PM ET._ FINANCIAL RELATIONSHIP DISCLOSURES ACR DISCLOSURE STATEMENT It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org. In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity. NATURE OF FINANCIAL RELATIONSHIPS All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to: * Advisor or review panel member * Consultant * Employee * Officer or Board Member * Grant/research support * Speaker/honoraria includes speaker’s bureau, symposia, and expert witness * Independent contractor * Executive role and/or ownership interest * Royalties and/or patent beneficiary * Intellectual property/patents * Stock options or bond holdings in a for-profit corporation or self-directed pension plan * Private investigator * Expert witness * Equity interest * Other: _specify details_ None: Has no relevant financial relationship(s) with ineligible companies to disclose. All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated. AUTHORS/PLANNERS * Beth Jonas, MD – No relevant financial relationships to disclose EDITORS AND REVIEWERS * Laurie Hughell, MPH, PA-C - No relevant financial relationships to disclose * Anneke Smith – No relevant financial relationships to disclose * Ben Smith, DMSc, PA-C, DFAAPA – No relevant financial relationships to disclose ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT The project was supported by Grant number 1 NU58DP006908-03-00 – Component A; Developing and Disseminating Programs to Build Sustainable Lupus Awareness, Knowledge, Skills and Partnerships. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Department of Health and Human Services, Centers for Disease Control and Prevention. EDUCATIONAL ACTIVITY POLICIES See ACR educational activity policies, including the online enduring activity refund policy.

ARC04: Imaging of Arthritis

Learn about different imaging modalities to aid in diagnosing rheumatic disease and making informed decisions regarding the most suitable treatments for patients.

ARC05: Coding and Practice Issues

ACTIVITY OVERVIEW The Advanced Rheumatology Course is a19-activity series for advanced practice providers and other professionals whoneed a deeper dive into rheumatology. The series covers how to assess and manage patients with rheumaticdisease, develop strategies to integrate NP/PAs into rheumatology practice, andimprove access to care for patients. The advanced information will helpexperienced practice providers function well in rheumatology and fosterinter-professional collaboration. In this activity, you will explore the significance of accurate documentation and coding procedures in practice and learn about the importance of ensuring the precision and suitability of reporting. ADVANCED RHEUMATOLOGY COURSE SERIES This activity is part of a series. See the other activities in the series below. * Advanced Rheumatology Course: All Activities * ARC01: Musculoskeletal Structure And Function And Inflammation And Immunity * ARC02: Framework for Clinical Decision Making in Rheumatology * ARC03: Laboratory Evaluation of Rheumatic Disease * ARC04: Imaging of Arthritis * ARC05: Coding and Practice Issues * ARC06: Therapeutic Interventions And Resources * ARC07: Osteoarthritis * ARC08: RA and Seronegative Inflammatory Arthropathies * ARC09: Systemic Lupus Erythematosus * ARC010: Systemic Inflammatory Conditions: Inflammatory Myopathy * ARC11: Vasculitis, Arteritis and PMR * ARC12: Crystal-Induced Arthropathies * ARC13: Pain Syndromes * ARC14: Spondyloarthritis * ARC15: Infection-Related Arthritis * ARC16: Osteoporosis And Other Metabolic Bone Disorders * ARC17: Comprehensive Overview of Juvenile Idiopathic Arthritis (JIA) * ARC18:Comprehensive Overview of Pediatric Connective Tissue Diseases (CTD) * ARC19: Pediatric Noninflammatory Musculoskeletal Pain Registration is discounted for ACR/ARP members. If you are not a member, consider joining ACR/ARP. TARGET AUDIENCE Advanced practice nurses and physician assistants. Fellows-in training, residents, students, primary care providers, and physical therapists may also benefit. LEARNING OBJECTIVES Upon completion of this activity, participants should be able to: * Discuss the scope of practice, regulatory structure, and reimbursement for nurse practitioners or physician assistants in rheumatology practices * Identify benefits of including nurse practitioners and physician assistants in rheumatology practices and strategies to facilitate successful practice relationships between rheumatologists and nurse practitioners and physician assistants * Apply evaluation and management services codes (E/M) for varied levels of clinical care in accordance with CMS Evaluation and Management Services Guidelines * Assign the most accurate and detailed Current Procedural Terminology (CPT) codes for individual professional services * Explain upcoding and downcoding, bundling and unbundling, and the use of CPT modifiers * Explain the Resource-Based Relative Value Scale (RBRVS) System for determining provider reimbursement CE & MOC INFORMATION ACCME ACCREDITATION STATEMENT The American College of Rheumatology (ACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AMA DESIGNATION STATEMENT The American College of Rheumatology designates this enduring material for a maximum of 1.00 _AMA PRA Category 1 Credit™_. Physicians should claim only the credit commensurate with the extent of their participation in the activity. See the ACRs CME Mission Statement. For more information, download the AMA PRA Booklet. _CME credit must be claimed by August 14, 2026, at 11:59 PM ET._ FINANCIAL RELATIONSHIP DISCLOSURES ACR DISCLOSURE STATEMENT It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org. In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity. NATURE OF FINANCIAL RELATIONSHIPS All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to: * Advisor or review panel member * Consultant * Employee * Officer or Board Member * Grant/research support * Speaker/honoraria includes speaker’s bureau, symposia, and expert witness * Independent contractor * Executive role and/or ownership interest * Royalties and/or patent beneficiary * Intellectual property/patents * Stock options or bond holdings in a for-profit corporation or self-directed pension plan * Private investigator * Expert witness * Equity interest * Other: _specify details_ None: Has no relevant financial relationship(s) with ineligible companies to disclose. All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated. AUTHORS/PLANNERS * J. Eugene Huffstutter, MD - No relevant financial relationships to disclose EDITORS AND REVIEWERS * Fredrica Smith, MD - No relevant financial relationships to disclose * Julie Lahti - No relevant financial relationships to disclose * Ben Smith, DMSc, PA-C, DFAAPA - No relevant financial relationships to disclose ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT The project was supported by Grant number 1 NU58DP006908-03-00 – Component A; Developing and Disseminating Programs to Build Sustainable Lupus Awareness, Knowledge, Skills and Partnerships. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Department of Health and Human Services, Centers for Disease Control and Prevention. EDUCATIONAL ACTIVITY POLICIES See ACR educational activity policies, including the online enduring activity refund policy.

ARC06: Therapeutic Interventions and Resources

ACTIVITY OVERVIEW The Advanced Rheumatology Course is a19-activity series for advanced practice providers and other professionals whoneed a deeper dive into rheumatology. The series covers how to assess and manage patients with rheumaticdisease, develop strategies to integrate NP/PAs into rheumatology practice, andimprove access to care for patients. The advanced information will helpexperienced practice providers function well in rheumatology and fosterinter-professional collaboration. In this activity, you will review a comprehensive presentation on therapeutic interventions, featuring the expertise of both physical therapists and occupational therapists. ADVANCED RHEUMATOLOGY COURSE SERIES This activity is part of a series. See the other activities in the series below. * Advanced Rheumatology Course: All Activities * ARC01: Musculoskeletal Structure And Function And Inflammation And Immunity * ARC02: Framework for Clinical Decision Making in Rheumatology * ARC03: Laboratory Evaluation of Rheumatic Disease * ARC04: Imaging of Arthritis * ARC05: Coding and Practice Issues * ARC06: Therapeutic Interventions And Resources * ARC07: Osteoarthritis * ARC08: RA and Seronegative Inflammatory Arthropathies * ARC09: Systemic Lupus Erythematosus * ARC010: Systemic Inflammatory Conditions: Inflammatory Myopathy * ARC11: Vasculitis, Arteritis and PMR * ARC12: Crystal-Induced Arthropathies * ARC13: Pain Syndromes * ARC14: Spondyloarthritis * ARC15: Infection-Related Arthritis * ARC16: Osteoporosis And Other Metabolic Bone Disorders * ARC17: Comprehensive Overview of Juvenile Idiopathic Arthritis (JIA) * ARC18:Comprehensive Overview of Pediatric Connective Tissue Diseases (CTD) * ARC19: Pediatric Noninflammatory Musculoskeletal Pain Registration is discounted for ACR/ARP members. If you are not a member, consider joining ACR/ARP. TARGET AUDIENCE Advanced practice nurses and physician assistants. Fellows-in training, residents, students, primary care providers, physical therapists, and researchers may also benefit. LEARNING OBJECTIVES Upon completion of this activity, participants should be able to: * Describe the components of the arthritis self-managementprogram in the management of rheumatic diseases and the benefits ofparticipation * Distinguish between cognitive behavioral models andbiomedical models of care in patients with rheumatic diseases * Analyze the benefits of participation in a rehabilitationprogram * Detect the benefits of physical modalities in managingsymptoms associated with rheumatic diseases * Integrate referrals to physical and occupational therapistsfor commonly occurring problems for people with rheumatic diseases into onesclinical practice * State the role of the following health care team members in thecare of persons with rheumatic diseases: rheumatologists, orthopedic surgeons,physiatrists, physical therapists, occupational therapists, psychologists andcounselors, dieticians, podiatrists/pedorthists, and social workers * Identify community resources for rheumatology healthprofessionals and children, adults, and families dealing with rheumaticdiseases CE & MOC INFORMATION ACCME ACCREDITATION STATEMENT The American College of Rheumatology (ACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AMA DESIGNATION STATEMENT The American College of Rheumatology designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. See the ACRs CME Mission Statement. For more information, download the AMA PRA Booklet. _CME credit must be claimed by August 14, 2026, at 11:59 PM ET._ FINANCIAL RELATIONSHIP DISCLOSURES ACR DISCLOSURE STATEMENT It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org. In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity. NATURE OF FINANCIAL RELATIONSHIPS All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to: * Advisor or review panel member * Consultant * Employee * Officer or Board Member * Grant/research support * Speaker/honoraria includes speaker’s bureau, symposia, and expert witness * Independent contractor * Executive role and/or ownership interest * Royalties and/or patent beneficiary * Intellectual property/patents * Stock options or bond holdings in a for-profit corporation or self-directed pension plan * Private investigator * Expert witness * Equity interest * Other: _specify details_ None: Has no relevant financial relationship(s) with ineligible companies to disclose. All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated. AUTHORS/PLANNERS * Donna Everix, MPH, PT - No relevant financial relationships to disclose * Jennifer Trizuto, DPT - No relevant financial relationships to disclose EDITORS AND REVIEWERS * Marie Westby, PT, PhD - Janssen Canada5; Ended 2020; Pfizer5; Ended 2020 * Julie Lahti - No relevant financial relationships to disclose * Ben Smith, DMSc, PA-C, DFAAPA - No relevant financial relationships to disclose ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT The project was supported by Grant number 1 NU58DP006908-03-00 – Component A; Developing and Disseminating Programs to Build Sustainable Lupus Awareness, Knowledge, Skills and Partnerships. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Department of Health and Human Services, Centers for Disease Control and Prevention. EDUCATIONAL ACTIVITY POLICIES See ACR educational activity policies, including the online enduring activity refund policy.

ARC07: Osteoarthritis

Learn how osteoarthritis adversely affects mobility, significantly contributes to disability rates, and imposes substantial a financial burden on society.

ARC08: RA and Seronegative Inflammatory Arthropathies

ACTIVITY OVERVIEW TheAdvanced Rheumatology Course is a 19-activity series for advanced practiceproviders and other professionals who need a deeper dive intorheumatology. The series covers how toassess and manage patients with rheumatic disease, develop strategies tointegrate NP/PAs into rheumatology practice, and improve access to care forpatients. The advanced information will help experienced practice providersfunction well in rheumatology and foster inter-professional collaboration. This activity reviews rheumatoid arthritis and seronegative inflammatory arthropathies, including how to distinguish between the three primary forms of joint pain. ADVANCED RHEUMATOLOGY COURSE SERIES This activity is part of a series. See the other activities in the series below. * Advanced Rheumatology Course: All Activities * ARC01: Musculoskeletal Structure And Function And Inflammation And Immunity * ARC02: Framework for Clinical Decision Making in Rheumatology * ARC03: Laboratory Evaluation of Rheumatic Disease * ARC04: Imaging of Arthritis * ARC05: Coding and Practice Issues * ARC06: Therapeutic Interventions And Resources * ARC07: Osteoarthritis * ARC08: RA and Seronegative Inflammatory Arthropathies * ARC09: Systemic Lupus Erythematosus * ARC010: Systemic Inflammatory Conditions: Inflammatory Myopathy * ARC11: Vasculitis, Arteritis and PMR * ARC12: Crystal-Induced Arthropathies * ARC13: Pain Syndromes * ARC14: Spondyloarthritis * ARC15: Infection-Related Arthritis * ARC16: Osteoporosis And Other Metabolic Bone Disorders * ARC17: Comprehensive Overview of Juvenile Idiopathic Arthritis (JIA) * ARC18:Comprehensive Overview of Pediatric Connective Tissue Diseases (CTD) * ARC19: Pediatric Noninflammatory Musculoskeletal Pain Registration is discounted for ACR/ARP members. If you are not a member, consider joining ACR/ARP. TARGET AUDIENCE Advanced practice nurses and physician assistants. Fellows-in training, residents, students, primary care providers, physical therapists, and researchers may also benefit. LEARNING OBJECTIVES Upon completion of this activity, participants should be able to: * Differentiate the three basic causes of joint pain, characterizing joint presentations and developing a limited differential diagnosis of joint pain * State the epidemiology, risk factors, and genetics associated with rheumatoid arthritis (RA) * Chart the progressive nature of the disease process, including the basic immunology of RA and the rationale for early aggressive therapy in RA * Categorize the distribution of joint involvement and extra-articular manifestations for early, advancing, and end-stage RA disease * Summarize laboratory abnormalities and the utility of rheumatoid factor, and cyclic citrullinated antibodies, and radiologic changes in RA * Discuss specific language of clinical trials, the utility of outcome measures, and the Disease Activity Score for RA * Integrate the historical and current context of treating RA, including the side effects of medications and the schedule for monitoring for adverse events, when caring for persons with RA CE & MOC INFORMATION ACCME ACCREDITATION STATEMENT The American College of Rheumatology (ACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AMA DESIGNATION STATEMENT The American College of Rheumatology designates this enduring material for a maximum of 2.25 _AMA PRA Category 1 Credit™_. Physicians should claim only the credit commensurate with the extent of their participation in the activity. See the ACRs CME Mission Statement. For more information, download the AMA PRA Booklet. _CME credit must be claimed by August 14, 2026, at 11:59 PM ET._ FINANCIAL RELATIONSHIP DISCLOSURES ACR DISCLOSURE STATEMENT It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org. In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity. NATURE OF FINANCIAL RELATIONSHIPS All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to: * Advisor or review panel member * Consultant * Employee * Officer or Board Member * Grant/research support * Speaker/honoraria includes speaker’s bureau, symposia, and expert witness * Independent contractor * Executive role and/or ownership interest * Royalties and/or patent beneficiary * Intellectual property/patents * Stock options or bond holdings in a for-profit corporation or self-directed pension plan * Private investigator * Expert witness * Equity interest * Other: _specify details_ None: Has no relevant financial relationship(s) with ineligible companies to disclose. All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated. AUTHOR * Gregory C. Gardner, MD, MACP – No relevant financial relationships to disclose EDITORS AND REVIEWERS * Sheila Arvikar, MD – No relevant financial relationships to disclose * Julie Lahti - No relevant financial relationships to disclose * Sonam Kiwalkar, MD – No relevant financial relationships to disclose ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT The project was supported by Grant number 1 NU58DP006908-03-00 – Component A; Developing and Disseminating Programs to Build Sustainable Lupus Awareness, Knowledge, Skills and Partnerships. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Department of Health and Human Services, Centers for Disease Control and Prevention. EDUCATIONAL ACTIVITY POLICIES See ACR educational activity policies, including the online enduring activity refund policy.

ARC09: Systemic Lupus Erythematosus

Explore the various manifestations of lupus, effective methods for diagnosing the condition, and optimal approaches for managing patients with lupus.

ARC10: Systemic Inflammatory Conditions

ACTIVITY OVERVIEW The Advanced Rheumatology Course is a19-activity series for advanced practice providers and other professionals whoneed a deeper dive into rheumatology. The series covers how to assess and manage patients with rheumaticdisease, develop strategies to integrate NP/PAs into rheumatology practice, andimprove access to care for patients. The advanced information will helpexperienced practice providers function well in rheumatology and fosterinter-professional collaboration. In this activity, you will learn how to accurately diagnose, administer appropriate treatments, and establish care plans for patients with inflammatory myopathy, Sjögren’s disease, and scleroderma. ADVANCED RHEUMATOLOGY COURSE SERIES This activity is part of a series. See the other activities in the series below. * Advanced Rheumatology Course: All Activities * ARC01: Musculoskeletal Structure And Function And Inflammation And Immunity * ARC02: Framework for Clinical Decision Making in Rheumatology * ARC03: Laboratory Evaluation of Rheumatic Disease * ARC04: Imaging of Arthritis * ARC05: Coding and Practice Issues * ARC06: Therapeutic Interventions And Resources * ARC07: Osteoarthritis * ARC08: RA and Seronegative Inflammatory Arthropathies * ARC09: Systemic Lupus Erythematosus * ARC010: Systemic Inflammatory Conditions: Inflammatory Myopathy * ARC11: Vasculitis, Arteritis and PMR * ARC12: Crystal-Induced Arthropathies * ARC13: Pain Syndromes * ARC14: Spondyloarthritis * ARC15: Infection-Related Arthritis * ARC16: Osteoporosis And Other Metabolic Bone Disorders * ARC17: Comprehensive Overview of Juvenile Idiopathic Arthritis (JIA) * ARC18:Comprehensive Overview of Pediatric Connective Tissue Diseases (CTD) * ARC19: Pediatric Noninflammatory Musculoskeletal Pain Registration is discounted for ACR/ARP members. If you are not a member, consider joining ACR/ARP. TARGET AUDIENCE Advanced practice nurses and physician assistants. Fellows-in training, residents, students, primary care providers, physical therapists, and researchers may also benefit. LEARNING OBJECTIVES Upon completion of this activity, participants should be able to: * Scleroderma: * Define scleroderma * Describe the epidemiology and pathogenesis of scleroderma * Describe the clinical features, differential diagnosis, clinical course, and prognosis of scleroderma * Discuss the treatment of scleroderma * Discuss future directions in assessing and managing immune-mediated disorders (scleroderma and idiopathic inflammatory myositis) * Idiopathic Inflammatory Myositis (IIM) * Define idiopathic inflammatory myositis, or IIM * Describe the epidemiology and pathogenesis of IIM * Describe the clinical features, differential diagnosis, clinical course, and prognosis of IIM * Discuss the treatment of IIM * Discuss future directions in assessing and managing immune-mediated disorders (scleroderma and idiopathic inflammatory myositis) * Sjögren’s syndrome (SS) * Define Sjögren’s syndrome (SS) * Describe the epidemiology and pathogenesis of SS * Describe the clinical features, differential diagnosis, clinical course, and prognosis of SS * Discuss the treatment of SS * Discuss future directions in assessing and managing SS CE & MOC INFORMATION ACCME ACCREDITATION STATEMENT The American College of Rheumatology (ACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AMA DESIGNATION STATEMENT The American College of Rheumatology designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. See the ACRs CME Mission Statement. For more information, download the AMA PRA Booklet. _CME credit must be claimed by August 14, 2026, at 11:59 PM ET._ FINANCIAL RELATIONSHIP DISCLOSURES ACR DISCLOSURE STATEMENT It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org. In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity. NATURE OF FINANCIAL RELATIONSHIPS All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to: * Advisor or review panel member * Consultant * Employee * Officer or Board Member * Grant/research support * Speaker/honoraria includes speaker’s bureau, symposia, and expert witness * Independent contractor * Executive role and/or ownership interest * Royalties and/or patent beneficiary * Intellectual property/patents * Stock options or bond holdings in a for-profit corporation or self-directed pension plan * Private investigator * Expert witness * Equity interest * Other: _specify details_ None: Has no relevant financial relationship(s) with ineligible companies to disclose. All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated. AUTHORS/PLANNERS * Jason Kolfenbach, MD: ChemoCentryx5 * Tara Skorupa, MD: No relevant financial relationships to disclose EDITORS AND REVIEWERS * Zsuzsanna McMahon – No relevant financial relationships to disclose * Marcy Bolster, MD – AbbVie2; American Board of Internal Medicine: Chair, ABIM Rheumatology Board6; Amgen2; Corbus Pharmaceuticals2; Cumberland2; Genentech2; Gilead Sciences5; Johnson & Johnson1; Pfizer2 * Julie Lahti – No relevant financial relationships to disclose ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT The project was supported by Grant number 1 NU58DP006908-03-00 – Component A; Developing and Disseminating Programs to Build Sustainable Lupus Awareness, Knowledge, Skills and Partnerships. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Department of Health and Human Services, Centers for Disease Control and Prevention. EDUCATIONAL ACTIVITY POLICIES See ACR educational activity policies, including the online enduring activity refund policy.

ARC11: Vasculitis, Arteritis and PMR

ACTIVITY OVERVIEW The Advanced Rheumatology Course is a19-activity series for advanced practice providers and other professionals whoneed a deeper dive into rheumatology. The series covers how to assess and manage patients with rheumaticdisease, develop strategies to integrate NP/PAs into rheumatology practice, andimprove access to care for patients. The advanced information will helpexperienced practice providers function well in rheumatology and fosterinter-professional collaboration. In this activity, you will review the epidemiology, clinical features, differential diagnoses, treatment options, and outcomes concerning vasculitis and other vasculitides. ADVANCED RHEUMATOLOGY COURSE SERIES This activity is part of a series. See the other activities in the series below. * Advanced Rheumatology Course: All Activities * ARC01: Musculoskeletal Structure And Function And Inflammation And Immunity * ARC02: Framework for Clinical Decision Making in Rheumatology * ARC03: Laboratory Evaluation of Rheumatic Disease * ARC04: Imaging of Arthritis * ARC05: Coding and Practice Issues * ARC06: Therapeutic Interventions And Resources * ARC07: Osteoarthritis * ARC08: RA and Seronegative Inflammatory Arthropathies * ARC09: Systemic Lupus Erythematosus * ARC010: Systemic Inflammatory Conditions: Inflammatory Myopathy * ARC11: Vasculitis, Arteritis and PMR * ARC12: Crystal-Induced Arthropathies * ARC13: Pain Syndromes * ARC14: Spondyloarthritis * ARC15: Infection-Related Arthritis * ARC16: Osteoporosis And Other Metabolic Bone Disorders * ARC17: Comprehensive Overview of Juvenile Idiopathic Arthritis (JIA) * ARC18:Comprehensive Overview of Pediatric Connective Tissue Diseases (CTD) * ARC19: Pediatric Noninflammatory Musculoskeletal Pain Registration is discounted for ACR/ARP members. If you are not a member, consider joining ACR/ARP. TARGET AUDIENCE Advanced practice nurses and physician assistants. Fellows-in training, residents, students, primary care providers, physical therapists, and researchers may also benefit. LEARNING OBJECTIVES Upon completion of this activity, participants should be able to: * Define vasculitis and describe the clinical features and the spectrum of disease entities in which vasculitis is seen * Describe the epidemiology, clinical features, differential diagnosis, treatment, and outcome for polymyalgia rheumatica (PMR) * Describe the epidemiology, clinical features, differential diagnosis, treatment, and outcome of giant cell arteritis (GCA) * Describe the epidemiology, clinical features, differential diagnosis, treatment, and outcome of granulomatosis with polyangiitis (GPA) * Describe the epidemiology, clinical features, differential diagnosis, treatment, and outcome of polyarteritis nodosa * Describe cutaneous vasculitis and its potential causes, diagnostic evaluation, and therapeutic principles CE & MOC INFORMATION ACCME ACCREDITATION STATEMENT The American College of Rheumatology (ACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AMA DESIGNATION STATEMENT The American College of Rheumatology designates this enduring material for a maximum of 1.25 _AMA PRA Category 1 Credit™_. Physicians should claim only the credit commensurate with the extent of their participation in the activity. See the ACRs CME Mission Statement. For more information, download the AMA PRA Booklet. _CME credit must be claimed by August 14, 2026, at 11:59 PM ET._ FINANCIAL RELATIONSHIP DISCLOSURES ACR DISCLOSURE STATEMENT It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org. In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity. NATURE OF FINANCIAL RELATIONSHIPS All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to: * Advisor or review panel member * Consultant * Employee * Officer or Board Member * Grant/research support * Speaker/honoraria includes speaker’s bureau, symposia, and expert witness * Independent contractor * Executive role and/or ownership interest * Royalties and/or patent beneficiary * Intellectual property/patents * Stock options or bond holdings in a for-profit corporation or self-directed pension plan * Private investigator * Expert witness * Equity interest * Other: _specify details_ None: Has no relevant financial relationship(s) with ineligible companies to disclose. All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated. AUTHORS/PLANNERS * Anisha Dua, MD - AbbVie/Abbott5, 8; ChemoCentryx5; Novartis5 * Josh Waytz, MD – No relevant financial relationships to disclose EDITORS AND REVIEWERS * Paul Monach, MD, PhD – Celgene1; Chemocentryx6; Kiniksa * Anneke Smith – No relevant financial relationships to disclose * Marcy Bolster, MD – AbbVie2; American Board of Internal Medicine: Chair, ABIM Rheumatology Board6; Amgen2; Corbus Pharmaceuticals2; Cumberland2; Genentech2; Gilead Sciences5; Johnson & Johnson1; Pfizer2 ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT The project was supported by Grant number 1 NU58DP006908-03-00 – Component A; Developing and Disseminating Programs to Build Sustainable Lupus Awareness, Knowledge, Skills and Partnerships. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Department of Health and Human Services, Centers for Disease Control and Prevention. EDUCATIONAL ACTIVITY POLICIES See ACR educational activity policies, including the online enduring activity refund policy.

ARC12: Crystal-induced Arthropathies

ACTIVITY OVERVIEW The Advanced Rheumatology Course is a19-activity series for advanced practice providers and other professionals whoneed a deeper dive into rheumatology. The series covers how to assess and manage patients with rheumaticdisease, develop strategies to integrate NP/PAs into rheumatology practice, andimprove access to care for patients. The advanced information will helpexperienced practice providers function well in rheumatology and fosterinter-professional collaboration. In this activity, you will learn to recognize diverse clinical presentations, underlying causes, pertinent diagnostic examinations, and effective management strategies for crystal deposition disorders. ADVANCED RHEUMATOLOGY COURSE SERIES This activity is part of a series. See the other activities in the series below. * Advanced Rheumatology Course: All Activities * ARC01: Musculoskeletal Structure And Function And Inflammation And Immunity * ARC02: Framework for Clinical Decision Making in Rheumatology * ARC03: Laboratory Evaluation of Rheumatic Disease * ARC04: Imaging of Arthritis * ARC05: Coding and Practice Issues * ARC06: Therapeutic Interventions And Resources * ARC07: Osteoarthritis * ARC08: RA and Seronegative Inflammatory Arthropathies * ARC09: Systemic Lupus Erythematosus * ARC010: Systemic Inflammatory Conditions: Inflammatory Myopathy * ARC11: Vasculitis, Arteritis and PMR * ARC12: Crystal-Induced Arthropathies * ARC13: Pain Syndromes * ARC14: Spondyloarthritis * ARC15: Infection-Related Arthritis * ARC16: Osteoporosis And Other Metabolic Bone Disorders * ARC17: Comprehensive Overview of Juvenile Idiopathic Arthritis (JIA) * ARC18:Comprehensive Overview of Pediatric Connective Tissue Diseases (CTD) * ARC19: Pediatric Noninflammatory Musculoskeletal Pain Registration is discounted for ACR/ARP members. If you are not a member, consider joining ACR/ARP. TARGET AUDIENCE Advanced practice nurses and physician assistants. Fellows-in training, residents, students, primary care providers, physical therapists, and researchers may also benefit. LEARNING OBJECTIVES Upon completion of this activity, participants should be able to: * Cite the common crystal depositiondisorders * Recognize the clinicalpresentation, causes, relevant diagnostic tests, and management of gout * Identify the clinicalpresentation; causes, relevant diagnostic tests, and management of calciumpyrophosphate dehydrate (CPPD) deposition disease * Discuss the clinical presentation,causes, relevant diagnostic tests, and management of basic calcium phosphate(BCP) deposition disease * State the clinical presentation,causes, relevant diagnostic tests, and management of oddball crystals * Summarize future directions forcrystal-induced arthropathies CE & MOC INFORMATION ACCME ACCREDITATION STATEMENT The American College of Rheumatology (ACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AMA DESIGNATION STATEMENT The American College of Rheumatology designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. See the ACRs CME Mission Statement. For more information, download the AMA PRA Booklet. _CME credit must be claimed by August 14, 2026, at 11:59 PM ET._ FINANCIAL RELATIONSHIP DISCLOSURES ACR DISCLOSURE STATEMENT It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org. In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity. NATURE OF FINANCIAL RELATIONSHIPS All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to: * Advisor or review panel member * Consultant * Employee * Officer or Board Member * Grant/research support * Speaker/honoraria includes speaker’s bureau, symposia, and expert witness * Independent contractor * Executive role and/or ownership interest * Royalties and/or patent beneficiary * Intellectual property/patents * Stock options or bond holdings in a for-profit corporation or self-directed pension plan * Private investigator * Expert witness * Equity interest * Other: _specify details_ None: Has no relevant financial relationship(s) with ineligible companies to disclose. All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated. AUTHORS * Puja Khanna, MD – Author: Puja Khanna, MD – DYVE2; Horizon1,2,5; Select1,2 EDITORS AND REVIEWERS * Chio Yokose, MD – No relevant financial relationships to disclose * Anneke Smith – No relevant financial relationships to disclose * Sonam Kiwalkar, MD – No relevant financial relationships to disclose ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT The project was supported by Grant number 1 NU58DP006908-03-00 – Component A; Developing and Disseminating Programs to Build Sustainable Lupus Awareness, Knowledge, Skills and Partnerships. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Department of Health and Human Services, Centers for Disease Control and Prevention. EDUCATIONAL ACTIVITY POLICIES See ACR educational activity policies, including the online enduring activity refund policy.

ARC13: Pain Syndromes

Increase your knowledge on pain syndromes for your patients with rheumatic disease and learn about delivering optimal patient care.

ARC14: Spondyloarthritis

ACTIVITY OVERVIEW The Advanced Rheumatology Course is a19-activity series for advanced practice providers and other professionals whoneed a deeper dive into rheumatology. The series covers how to assess and manage patients with rheumaticdisease, develop strategies to integrate NP/PAs into rheumatology practice, andimprove access to care for patients. The advanced information will helpexperienced practice providers function well in rheumatology and fosterinter-professional collaboration. This activity reviews spondyloarthritis, including axial spondyloarthritis, psoriatic arthritis, reactive arthritis, and inflammatory bowel disease-associated arthritis. ADVANCED RHEUMATOLOGY COURSE SERIES This activity is part of a series. See the other activities in the series below. * Advanced Rheumatology Course: All Activities * ARC01: Musculoskeletal Structure And Function And Inflammation And Immunity * ARC02: Framework for Clinical Decision Making in Rheumatology * ARC03: Laboratory Evaluation of Rheumatic Disease * ARC04: Imaging of Arthritis * ARC05: Coding and Practice Issues * ARC06: Therapeutic Interventions And Resources * ARC07: Osteoarthritis * ARC08: RA and Seronegative Inflammatory Arthropathies * ARC09: Systemic Lupus Erythematosus * ARC010: Systemic Inflammatory Conditions: Inflammatory Myopathy * ARC11: Vasculitis, Arteritis and PMR * ARC12: Crystal-Induced Arthropathies * ARC13: Pain Syndromes * ARC14: Spondyloarthritis * ARC15: Infection-Related Arthritis * ARC16: Osteoporosis And Other Metabolic Bone Disorders * ARC17: Comprehensive Overview of Juvenile Idiopathic Arthritis (JIA) * ARC18:Comprehensive Overview of Pediatric Connective Tissue Diseases (CTD) * ARC19: Pediatric Noninflammatory Musculoskeletal Pain Registration is discounted for ACR/ARP members. If you are not a member, consider joining ACR/ARP. TARGET AUDIENCE Advanced practice nurses and physician assistants. Fellows-in training, residents, students, primary care providers, physical therapists, and researchers may also benefit. LEARNING OBJECTIVES Upon completion of this activity, participants should be able to: * Define spondyloarthritis, thespectrum of conditions, and their common clinical features * Differentiate between mechanicalback pain and inflammatory back pain * Enumerate the classificationcriteria for axial spondyloarthritis, peripheral spondyloarthritis, ankylosingspondylitis, and psoriatic arthritis * Develop a plan for how toinvestigate a patient with inflammatory back pain * Discuss the epidemiology andpathogenesis of spondyloarthritis * Describe the clinical course andprognosis of ankylosing spondylitis, reactive arthritis, psoriatic arthritis(PA), and inflammatory bowel disease (IBD)-associated arthritis * Integrate in practicenonpharmacologic and pharmacologic disease management choices CE & MOC INFORMATION ACCME ACCREDITATION STATEMENT The American College of Rheumatology (ACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AMA DESIGNATION STATEMENT The American College of Rheumatology designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. See the ACRs CME Mission Statement. For more information, download the AMA PRA Booklet. _CME credit must be claimed by August 14, 2026, at 11:59 PM ET._ FINANCIAL RELATIONSHIP DISCLOSURES ACR DISCLOSURE STATEMENT It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org. In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity. NATURE OF FINANCIAL RELATIONSHIPS All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to: * Advisor or review panel member * Consultant * Employee * Officer or Board Member * Grant/research support * Speaker/honoraria includes speaker’s bureau, symposia, and expert witness * Independent contractor * Executive role and/or ownership interest * Royalties and/or patent beneficiary * Intellectual property/patents * Stock options or bond holdings in a for-profit corporation or self-directed pension plan * Private investigator * Expert witness * Equity interest * Other: _specify details_ None: Has no relevant financial relationship(s) with ineligible companies to disclose. All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated. AUTHORS * Atul Deodhar, MD - AbbVie/Abbott528; Amgen528; BMS528; Boheringer Ingelheim528; Celgene528; Gilead528; Glapagos528; Janssen528; Lilly528; Novartis528; Pfizer528; UCB528 * Anand Kumthekar, MD – No relevant financial relationships to disclose PLANNERS, EDITORS AND REVIEWERS * Abhijeet Danve, MD – AbbVie/Abbott1; Novartis1 * Anneke Smith – No relevant financial relationships to disclose * Sonam Kiwalkar, MD – No relevant financial relationships to disclose ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT The project was supported by Grant number 1 NU58DP006908-03-00 – Component A; Developing and Disseminating Programs to Build Sustainable Lupus Awareness, Knowledge, Skills and Partnerships. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Department of Health and Human Services, Centers for Disease Control and Prevention. EDUCATIONAL ACTIVITY POLICIES See ACR educational activity policies, including the online enduring activity refund policy.

ARC15: Infection-related Arthritis

ACTIVITY OVERVIEW The Advanced Rheumatology Course is a19-activity series for advanced practice providers and other professionals whoneed a deeper dive into rheumatology. The series covers how to assess and manage patients with rheumaticdisease, develop strategies to integrate NP/PAs into rheumatology practice, andimprove access to care for patients. The advanced information will helpexperienced practice providers function well in rheumatology and fosterinter-professional collaboration. In this activity, you will learn about infection-related arthritis and septic arthritis, along with its associated rheumatic manifestations, including those related to HIV. ADVANCED RHEUMATOLOGY COURSE SERIES This activity is part of a series. See the other activities in the series below. * Advanced Rheumatology Course: All Activities * ARC01: Musculoskeletal Structure And Function And Inflammation And Immunity * ARC02: Framework for Clinical Decision Making in Rheumatology * ARC03: Laboratory Evaluation of Rheumatic Disease * ARC04: Imaging of Arthritis * ARC05: Coding and Practice Issues * ARC06: Therapeutic Interventions And Resources * ARC07: Osteoarthritis * ARC08: RA and Seronegative Inflammatory Arthropathies * ARC09: Systemic Lupus Erythematosus * ARC010: Systemic Inflammatory Conditions: Inflammatory Myopathy * ARC11: Vasculitis, Arteritis and PMR * ARC12: Crystal-Induced Arthropathies * ARC13: Pain Syndromes * ARC14: Spondyloarthritis * ARC15: Infection-Related Arthritis * ARC16: Osteoporosis And Other Metabolic Bone Disorders * ARC17: Comprehensive Overview of Juvenile Idiopathic Arthritis (JIA) * ARC18:Comprehensive Overview of Pediatric Connective Tissue Diseases (CTD) * ARC19: Pediatric Noninflammatory Musculoskeletal Pain Registration is discounted for ACR/ARP members. If you are not a member, consider joining ACR/ARP. TARGET AUDIENCE Advanced practice nurses and physician assistants. Fellows-in training, residents, students, primary care providers, physical therapists, and researchers may also benefit. LEARNING OBJECTIVES Upon completion of this activity, participants should be able to: * Differentiate between thedifferent types of septic arthritis, the pathogenesis, incidence, risk factors,diagnostic features, and the treatment for each type * Cite the epidemiology and identifythe clinical features and treatment of each stage of Lyme disease * Distinguish between the post-viralarthritides and the pathogenesis, clinical features, diagnostic studies, andtreatment for each disease * State the articular andnon-articular manifestations of HIV that mimic rheumatic diseases * Evaluate the articularmanifestations and clinical course of Hepatitis B and C * Apply the general principles ofdisease recognition and management in patients with suspected infectiousarthritis CE & MOC INFORMATION ACCME ACCREDITATION STATEMENT The American College of Rheumatology (ACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AMA DESIGNATION STATEMENT The American College of Rheumatology designates this enduring online activity for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. See the ACRs CME Mission Statement. For more information, download the AMA PRA Booklet. _CME credit must be claimed by August 14, 2026, at 11:59 PM ET._ FINANCIAL RELATIONSHIP DISCLOSURES ACR DISCLOSURE STATEMENT It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org. In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity. NATURE OF FINANCIAL RELATIONSHIPS All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to: * Advisor or review panel member * Consultant * Employee * Officer or Board Member * Grant/research support * Speaker/honoraria includes speaker’s bureau, symposia, and expert witness * Independent contractor * Executive role and/or ownership interest * Royalties and/or patent beneficiary * Intellectual property/patents * Stock options or bond holdings in a for-profit corporation or self-directed pension plan * Private investigator * Expert witness * Equity interest * Other: _specify details_ None: Has no relevant financial relationship(s) with ineligible companies to disclose. All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated. AUTHORS/PLANNERS * Robert A. Kalish, MD – No relevant financial relationships to disclose * Janet Hong, MD – No relevant financial relationships to disclose * Frank Scangarello, MD, PhD – No relevant financial relationships to disclose EDITORS AND REVIEWERS * Michael Battistone, MD – American Board of Internal Medicine Rheumatology Exam Committee6: Advisor or Review Panel member * Anneke Smith – No relevant financial relationships to disclose * Marcy Bolster, MD – AbbVie2; American Board of Internal Medicine: Chair, ABIM Rheumatology Board6; Amgen2; Corbus Pharmaceuticals2; Cumberland2; Genentech2; Gilead Sciences5; Johnson & Johnson1; Pfizer2 ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT The project was supported by Grant number 1 NU58DP006908-03-00 – Component A; Developing and Disseminating Programs to Build Sustainable Lupus Awareness, Knowledge, Skills and Partnerships. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Department of Health and Human Services, Centers for Disease Control and Prevention. EDUCATIONAL ACTIVITY POLICIES See ACR educational activity policies, including the online enduring activity refund policy.

ARC16: Osteoporosis and Other Metabolic Bone Disorders

ACTIVITY OVERVIEW The Advanced Rheumatology Course is a19-activity series for advanced practice providers and other professionals who need a deeper dive into rheumatology. The series covers how to assess and manage patients with rheumatic disease, develop strategies to integrate NP/PAs into rheumatology practice, and improve access to care for patients. The advanced information will help experienced practice providers function well in rheumatology and foster inter-professional collaboration. This activity explores osteoporosis and other metabolic bone disorders, including how to care for patients with these conditions. ADVANCED RHEUMATOLOGY COURSE SERIES This activity is part of a series. See the other activities in the series below. * Advanced Rheumatology Course: All Activities * ARC01: Musculoskeletal Structure And Function And Inflammation And Immunity * ARC02: Framework for Clinical Decision Making in Rheumatology * ARC03: Laboratory Evaluation of Rheumatic Disease * ARC04: Imaging of Arthritis * ARC05: Coding and Practice Issues * ARC06: Therapeutic Interventions And Resources * ARC07: Osteoarthritis * ARC08: RA and Seronegative Inflammatory Arthropathies * ARC09: Systemic Lupus Erythematosus * ARC010: Systemic Inflammatory Conditions: Inflammatory Myopathy * ARC11: Vasculitis, Arteritis and PMR * ARC12: Crystal-Induced Arthropathies * ARC13: Pain Syndromes * ARC14: Spondyloarthritis * ARC15: Infection-Related Arthritis * ARC16: Osteoporosis And Other Metabolic Bone Disorders * ARC17: Comprehensive Overview of Juvenile Idiopathic Arthritis (JIA) * ARC18:Comprehensive Overview of Pediatric Connective Tissue Diseases (CTD) * ARC19: Pediatric Noninflammatory Musculoskeletal Pain Registration is discounted for ACR/ARP members. If you are not a member, consider joining ACR/ARP. TARGET AUDIENCE Advanced practice nurses and physician assistants. Fellows-in training, residents, students, primary care providers, physical therapists, and researchers may also benefit. LEARNING OBJECTIVES Upon completion of this activity, participants should be able to: * Recognize the risk factors for fracture in women with postmenopausal osteoporosis * Interpret bone density reports and demonstrate how to use bone density studies for clinical decision making * Describe the important nutritional components of bone health including calcium and Vitamin D and the consequences of deficiencies * Formulate basic treatment plans for patients with postmenopausal osteoporosis * Design a clinical profile for men at risk for osteoporosis and discuss a metabolic workup for men with osteoporosis * Contrast the pathophysiology of glucocorticoid induced osteoporosis (GIOP) with postmenopausal osteoporosis and formulates treatment plans for patients on glucocorticoids therapy * Evaluate the epidemiology, pathophysiology, clinical and radiological aspects, and a treatment plan for Pagets disease CE & MOC INFORMATION ACCME ACCREDITATION STATEMENT The American College of Rheumatology (ACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AMA DESIGNATION STATEMENT The American College of Rheumatology designates this enduring material for a maximum of 2.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. See the ACRs CME Mission Statement. For more information, download the AMA PRA Booklet. _CME credit must be claimed by August 14, 2026, at 11:59 PM ET._ FINANCIAL RELATIONSHIP DISCLOSURES ACR DISCLOSURE STATEMENT It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org. In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity. NATURE OF FINANCIAL RELATIONSHIPS All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to: * Advisor or review panel member * Consultant * Employee * Officer or Board Member * Grant/research support * Speaker/honoraria includes speaker’s bureau, symposia, and expert witness * Independent contractor * Executive role and/or ownership interest * Royalties and/or patent beneficiary * Intellectual property/patents * Stock options or bond holdings in a for-profit corporation or self-directed pension plan * Private investigator * Expert witness * Equity interest * Other: _specify details_ None: Has no relevant financial relationship(s) with ineligible companies to disclose. All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated. AUTHOR * Sarah Keller, MD – No relevant financial relationships to disclose EDITORS AND REVIEWERS * Alfred Denio, MD – Abbvie8; Bristol-Myers Squibb5 * Marcy Bolster, MD – AbbVie2; American Board of Internal Medicine: Chair, ABIM Rheumatology Board6; Amgen2; Corbus Pharmaceuticals2; Cumberland2; Genentech2; Gilead Sciences5; Johnson & Johnson1; Pfizer2 * Julie Lahti – No relevant financial relationships to disclose ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT The project was supported by Grant number 1 NU58DP006908-03-00 – Component A; Developing and Disseminating Programs to Build Sustainable Lupus Awareness, Knowledge, Skills and Partnerships. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Department of Health and Human Services, Centers for Disease Control and Prevention. EDUCATIONAL ACTIVITY POLICIES See ACR educational activity policies, including the online enduring activity refund policy.

ARC17: Comprehensive Overview of Juvenile Idiopathic Arthritis (JIA)

ACTIVITY OVERVIEW The Advanced Rheumatology Course is a19-activity series for advanced practice providers and other professionals whoneed a deeper dive into rheumatology. The series covers how to assess and manage patients with rheumaticdisease, develop strategies to integrate NP/PAs into rheumatology practice, andimprove access to care for patients. The advanced information will helpexperienced practice providers function well in rheumatology and fosterinter-professional collaboration. This activity covers the knowledge and skills needed to effectively evaluate, treat, and support patients with juvenile idiopathic arthritis (JIA). ADVANCED RHEUMATOLOGY COURSE SERIES This activity is part of a series. See the other activities in the series below. * Advanced Rheumatology Course: All Activities * ARC01: Musculoskeletal Structure And Function And Inflammation And Immunity * ARC02: Framework for Clinical Decision Making in Rheumatology * ARC03: Laboratory Evaluation of Rheumatic Disease * ARC04: Imaging of Arthritis * ARC05: Coding and Practice Issues * ARC06: Therapeutic Interventions And Resources * ARC07: Osteoarthritis * ARC08: RA and Seronegative Inflammatory Arthropathies * ARC09: Systemic Lupus Erythematosus * ARC010: Systemic Inflammatory Conditions: Inflammatory Myopathy * ARC11: Vasculitis, Arteritis and PMR * ARC12: Crystal-Induced Arthropathies * ARC13: Pain Syndromes * ARC14: Spondyloarthritis * ARC15: Infection-Related Arthritis * ARC16: Osteoporosis And Other Metabolic Bone Disorders * ARC17: Comprehensive Overview of Juvenile Idiopathic Arthritis (JIA) * ARC18:Comprehensive Overview of Pediatric Connective Tissue Diseases (CTD) * ARC19: Pediatric Noninflammatory Musculoskeletal Pain Registration is discounted for ACR/ARP members. If you are not a member, consider joining ACR/ARP. TARGET AUDIENCE Advanced practice nurses and physician assistants. Fellows-in training, residents, students, primary care providers, physical therapists, and researchers may also benefit. LEARNING OBJECTIVES Upon completion of this activity, participants should be able to: * Identify symptoms and signs consistent with juvenile idiopathic arthritis * Complete a comprehensive evaluation when juvenile idiopathic arthritis is suspected * Design a patient-centered management plan for children with juvenile idiopathic arthritis * Teach patients and their parents concerning juvenile idiopathic arthritis in a supportive and motivating manner CE & MOC INFORMATION ACCME ACCREDITATION STATEMENT The American College of Rheumatology (ACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AMA DESIGNATION STATEMENT The American College of Rheumatology designates this enduring material for a maximum of 1.25 _AMA PRA Category 1 Credit™_. Physicians should claim only the credit commensurate with the extent of their participation in the activity. See the ACRs CME Mission Statement. For more information, download the AMA PRA Booklet. _CME credit must be claimed by August 14, 2026, at 11:59 PM ET._ FINANCIAL RELATIONSHIP DISCLOSURES ACR DISCLOSURE STATEMENT It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org. In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity. NATURE OF FINANCIAL RELATIONSHIPS All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to: * Advisor or review panel member * Consultant * Employee * Officer or Board Member * Grant/research support * Speaker/honoraria includes speaker’s bureau, symposia, and expert witness * Independent contractor * Executive role and/or ownership interest * Royalties and/or patent beneficiary * Intellectual property/patents * Stock options or bond holdings in a for-profit corporation or self-directed pension plan * Private investigator * Expert witness * Equity interest * Other: _specify details_ None: Has no relevant financial relationship(s) with ineligible companies to disclose. All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated. AUTHOR * Betsy Roth-Wojcicki, RN, MS, CPNP-PC - No relevant financial relationships to disclose EDITORS AND REVIEWERS * Heather Benham, APRN, CPNP, DNP, RhMSUS – No relevant financial relationships to disclose * Anneke Smith - No relevant financial relationships to disclose * Ben Smith, DMSc, PA-C, DFAAPA – No relevant financial relationships to disclose ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT The project was supported by Grant number 1 NU58DP006908-03-00 – Component A; Developing and Disseminating Programs to Build Sustainable Lupus Awareness, Knowledge, Skills and Partnerships. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Department of Health and Human Services, Centers for Disease Control and Prevention. EDUCATIONAL ACTIVITY POLICIES See ACR educational activity policies, including the online enduring activity refund policy.

ARC18: Comprehensive Overview of Pediatric Connective Tissue Diseases (CTD)

ACTIVITY OVERVIEW The Advanced Rheumatology Course is a19-activity series for advanced practice providers and other professionals whoneed a deeper dive into rheumatology. The series covers how to assess and manage patients with rheumaticdisease, develop strategies to integrate NP/PAs into rheumatology practice, andimprove access to care for patients. The advanced information will helpexperienced practice providers function well in rheumatology and fosterinter-professional collaboration. In this activity, you will explore the necessary knowledge and skills to effectively evaluate, treat, and educate pediatric connective tissue disease patients and their families. ADVANCED RHEUMATOLOGY COURSE SERIES This activity is part of a series. See the other activities in the series below. * Advanced Rheumatology Course: All Activities * ARC01: Musculoskeletal Structure And Function And Inflammation And Immunity * ARC02: Framework for Clinical Decision Making in Rheumatology * ARC03: Laboratory Evaluation of Rheumatic Disease * ARC04: Imaging of Arthritis * ARC05: Coding and Practice Issues * ARC06: Therapeutic Interventions And Resources * ARC07: Osteoarthritis * ARC08: RA and Seronegative Inflammatory Arthropathies * ARC09: Systemic Lupus Erythematosus * ARC010: Systemic Inflammatory Conditions: Inflammatory Myopathy * ARC11: Vasculitis, Arteritis and PMR * ARC12: Crystal-Induced Arthropathies * ARC13: Pain Syndromes * ARC14: Spondyloarthritis * ARC15: Infection-Related Arthritis * ARC16: Osteoporosis And Other Metabolic Bone Disorders * ARC17: Comprehensive Overview of Juvenile Idiopathic Arthritis (JIA) * ARC18:Comprehensive Overview of Pediatric Connective Tissue Diseases (CTD) * ARC19: Pediatric Noninflammatory Musculoskeletal Pain Registration is discounted for ACR/ARP members. If you are not a member, consider joining ACR/ARP. TARGET AUDIENCE Advanced practice nurses and physician assistants. Fellows-in training, residents, students, primary care providers, physical therapists, and researchers may also benefit. LEARNING OBJECTIVES Upon completion of this activity, participants should be able to: * Identify the three most common connective tissue diseases (CTDs) in children: systemic lupus erythematosus, juvenile dermatomyositis and scleroderma * Recognize the epidemiology and pathogenesis, clinical features, differential diagnosis, clinical course and prognosis for these three CTDs * Complete a comprehensive evaluation for each of these three CTDs * Design a management plan for each of these three CTDs CE & MOC INFORMATION ACCME ACCREDITATION STATEMENT The American College of Rheumatology (ACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AMA DESIGNATION STATEMENT The American College of Rheumatology designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. See the ACRs CME Mission Statement. For more information, download the AMA PRA Booklet. _CME credit must be claimed by August 14, 2026, at 11:59 PM ET._ FINANCIAL RELATIONSHIP DISCLOSURES ACR DISCLOSURE STATEMENT It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org. In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity. NATURE OF FINANCIAL RELATIONSHIPS All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to: * Advisor or review panel member * Consultant * Employee * Officer or Board Member * Grant/research support * Speaker/honoraria includes speaker’s bureau, symposia, and expert witness * Independent contractor * Executive role and/or ownership interest * Royalties and/or patent beneficiary * Intellectual property/patents * Stock options or bond holdings in a for-profit corporation or self-directed pension plan * Private investigator * Expert witness * Equity interest * Other: _specify details_ None: Has no relevant financial relationship(s) with ineligible companies to disclose. All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated. AUTHORS * Heather Benham, DNP, APRN, CPNP-PC, RhMSUS – No relevant financial relationships to disclose EDITORS AND REVIEWERS * Natasha Ruth, MD, MS – No relevant financial relationships to disclose * Marcy Bolster, MD – AbbVie2; American Board of Internal Medicine: Chair, ABIM Rheumatology Board6; Amgen2; Corbus Pharmaceuticals2; Cumberland2; Genentech2; Gilead Sciences5; Johnson & Johnson1; Pfizer2 * Julie Lahti – No relevant financial relationships to disclose ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT The project was supported by Grant number 1 NU58DP006908-03-00 – Component A; Developing and Disseminating Programs to Build Sustainable Lupus Awareness, Knowledge, Skills and Partnerships. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Department of Health and Human Services, Centers for Disease Control and Prevention. EDUCATIONAL ACTIVITY POLICIES See ACR educational activity policies, including the online enduring activity refund policy.

ARC19: Pediatric Noninflammatory Musculoskeletal Pain

ACTIVITY OVERVIEW The Advanced Rheumatology Course is a19-activity series for advanced practice providers and other professionals whoneed a deeper dive into rheumatology. The series covers how to assess and manage patients with rheumaticdisease, develop strategies to integrate NP/PAs into rheumatology practice, andimprove access to care for patients. The advanced information will helpexperienced practice providers function well in rheumatology and fosterinter-professional collaboration. In this activity, you will learn to distinguish between individuals who exhibit signs of inflammation and those experiencing non-inflammatory pain, and review each of their common patterns. ADVANCED RHEUMATOLOGY COURSE SERIES This activity is part of a series. See the other activities in the series below. * Advanced Rheumatology Course: All Activities * ARC01: Musculoskeletal Structure And Function And Inflammation And Immunity * ARC02: Framework for Clinical Decision Making in Rheumatology * ARC03: Laboratory Evaluation of Rheumatic Disease * ARC04: Imaging of Arthritis * ARC05: Coding and Practice Issues * ARC06: Therapeutic Interventions And Resources * ARC07: Osteoarthritis * ARC08: RA and Seronegative Inflammatory Arthropathies * ARC09: Systemic Lupus Erythematosus * ARC010: Systemic Inflammatory Conditions: Inflammatory Myopathy * ARC11: Vasculitis, Arteritis and PMR * ARC12: Crystal-Induced Arthropathies * ARC13: Pain Syndromes * ARC14: Spondyloarthritis * ARC15: Infection-Related Arthritis * ARC16: Osteoporosis And Other Metabolic Bone Disorders * ARC17: Comprehensive Overview of Juvenile Idiopathic Arthritis (JIA) * ARC18:Comprehensive Overview of Pediatric Connective Tissue Diseases (CTD) * ARC19: Pediatric Noninflammatory Musculoskeletal Pain Registration is discounted for ACR/ARP members. If you are not a member, consider joining ACR/ARP. TARGET AUDIENCE Advanced practice nurses and physician assistants. Fellows-in training, residents, students, primary care providers, physical therapists, and researchers may also benefit. LEARNING OBJECTIVES Upon completion of this activity, participants should be able to: * Differentiate the clinical features and presentation of noninflammatory pain syndromes in children from other causes of musculoskeletal pain including inflammatory and traumatic disorders * Diagnose benign limb pain (growing pains), patellofemoral pain, and benign joint hypermobility pain based on presenting symptoms and exam findings * Describe the pathophysiology of central sensitization or amplified musculoskeletal pain syndromes, including complex regional pain syndrome and juvenile primary fibromyalgia syndrome * Counsel patients and families about the prognosis and treatment options for noninflammatory pain syndromes in children CE & MOC INFORMATION ACCME ACCREDITATION STATEMENT The American College of Rheumatology (ACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AMA DESIGNATION STATEMENT The American College of Rheumatology designates this enduring material for a maximum of 1.00 _AMA PRA Category 1 Credit™_. Physicians should claim only the credit commensurate with the extent of their participation in the activity. See the ACRs CME Mission Statement. For more information, download the AMA PRA Booklet. _CME credit must be claimed by August 14, 2026, at 11:59 PM ET._ FINANCIAL RELATIONSHIP DISCLOSURES ACR DISCLOSURE STATEMENT It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org. In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, ACR has implemented mechanisms prior to the planning and implementation of this CME activity to identify and mitigate all relevant financial relationships for all individuals in a position to control the content of this CME activity. NATURE OF FINANCIAL RELATIONSHIPS All individuals that participate in an ACR-sponsored activity and are able to change content or influence the content of the activity must disclose to the planning committee and audience all financial or other relationships with ineligible companies including, but not limited to: * Advisor or review panel member * Consultant * Employee * Officer or Board Member * Grant/research support * Speaker/honoraria includes speaker’s bureau, symposia, and expert witness * Independent contractor * Executive role and/or ownership interest * Royalties and/or patent beneficiary * Intellectual property/patents * Stock options or bond holdings in a for-profit corporation or self-directed pension plan * Private investigator * Expert witness * Equity interest * Other: _specify details_ None: Has no relevant financial relationship(s) with ineligible companies to disclose. All participants that created and/or were able to influence the content and delivery of this activity reported the following disclosures. All of the relevant financial relationships listed have been mitigated. AUTHOR * Bethany A. Marston, MD – No relevant financial relationships to disclose EDITORS AND REVIEWERS * Susan Shenoi, MS, MBBS, RhMSUS – Pfizer5 * Julie Lahti - No relevant financial relationships to disclose * Sonam Kiwalkar, MD – No relevant financial relationships to disclose ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT The project was supported by Grant number 1 NU58DP006908-03-00 – Component A; Developing and Disseminating Programs to Build Sustainable Lupus Awareness, Knowledge, Skills and Partnerships. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Department of Health and Human Services, Centers for Disease Control and Prevention. EDUCATIONAL ACTIVITY POLICIES See ACR educational activity policies, including the online enduring activity refund policy.